14 completed. 14 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
| Phase 3 | 2 | Completed 2 |
Follow Growth Hormone Deficiency: new trials by email Literature Review of Growth Hormone Deficiency trials Research Report on Growth Hormone Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) LUM-201 - Growth Hormone Deficiency | Phase 2 | Completed | Lumos Pharma | 15 | 2022-02-18 | 2026-05-15 |
| Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) LUM-201, rhGH Norditropin® pen (34 µg/kg) - Growth Hormone Deficiency | Phase 2 | Completed | Lumos Pharma | 104 | 2020-12-31 | 2026-06-17 |
| Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children Y-shape pegylated somatropin, Norditropin®, Norditropin - Growth Hormone Deficiency | Phase 2 / Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 434 | 2018-12-26 | 2024-01-24 |
| Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency GX-H9, Genotropin - Growth Hormone Deficiency | Phase 2 | Completed | Genexine, Inc. | 56 | 2016-01-18 | 2020-04-20 |
| Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency TV-1106, Recombinant human growth hormone - Growth Hormone Deficiency | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 52 | 2013-03-31 | 2021-12-10 |
| Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I) Norditropin SimpleXx (growth hormone) - Growth Hormone Deficiency | Phase 2 | Completed | Aarhus University Hospital | 8 | 2010-10-01 | 2014-01-09 |
| Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth hormone releasing hormone (GHRH) 1-44, Placebo - Abdominal Obesity, Growth Hormone Deficiency | Phase 2 | Completed | Massachusetts General Hospital | 60 | 2008-07-01 | 2017-12-13 |
| Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD). ARX201 - Growth Hormone Deficiency | Phase 2 | Completed | Ambrx, Inc. | 36 | 2008-07-01 | 2009-10-12 |
| Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure Somatotropin - Growth Hormone Deficiency, Chronic Heart Failure | Phase 2 | Completed | Federico II University | 28 | 2007-01-01 | 2012-10-18 |
| Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children pegylated Somatropin, Jintropin AQ - Growth Hormone Deficiency | Phase 2 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 101 | 2006-05-01 | 2017-07-31 |
| Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial Somatotropin - Heart Failure, Growth Hormone Deficiency | Phase 2 | Completed | Federico II University | 56 | 2004-12-01 | 2012-11-19 |
| Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters) sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group), amitriptyline, fluoxetine and tramadol alone (control group) - Fibromyalgia, Growth Hormone Deficiency | Phase 2 | Completed | Centro Medico Teknon | 2004-05-01 | 2007-07-06 | |
| Testosterone and Growth Hormone for Bone Loss in Men Testosterone plus somatropin, testosterone - Hypopituitarism, Hypogonadism | Phase 2 | Completed | University of Pennsylvania | 35 | 2004-03-01 | 2014-06-13 |
| Sustained Release Formulation of Somatropin (rDNA Origin)for Injection BPLG-003 - Growth Hormone Deficiency | Phase 2 / Phase 3 | Completed | BioPartners GmbH | 51 | 2003-06-01 | 2008-01-25 |
Dwarfism, Pituitary (14) · Fibromyalgia (1) · Heart Failure (1) · Hypogonadism (1) · Hypopituitarism (1) · Myocardial Ischemia (1) · Obesity, Abdominal (1)
Bone Diseases (14) · Bone Diseases, Developmental (14) · Bone Diseases, Endocrine (14) · Brain Diseases (14) · Central Nervous System Diseases (14) · Dwarfism (14) · Endocrine System Diseases (14) · Hypothalamic Diseases (14) · Musculoskeletal Diseases (14) · Nervous System Diseases (14) · Pituitary Diseases (14) · Hypopituitarism (13) · Body Weight (1) · Cardiovascular Diseases (1) · Gonadal Disorders (1)
Human Growth Hormone (5) · Growth Hormone (4) · Amitriptyline (1) · Control Groups (1) · Fluoxetine (1) · GX-H9 (1) · Growth Hormone-Releasing Hormone (1) · Testosterone (1) · Tramadol (1) · albusomatropin (1) · tesamorelin (1)
Federico II University (2) · Lumos Pharma (2) · Aarhus University Hospital (1) · Ambrx, Inc. (1) · BioPartners GmbH (1) · Centro Medico Teknon (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Genexine, Inc. (1) · Massachusetts General Hospital (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · University of Pennsylvania (1) · Xiamen Amoytop Biotech Co., Ltd. (1)
United States (5) · Hungary (2) · Israel (2) · Poland (2) · Ukraine (2) · Australia (1) · China (1) · Czechia (1) · Denmark (1) · Germany (1) · Greece (1) · Italy (1) · New Zealand (1) · Serbia (1) · Slovakia (1)
Albert Nadal, MD (1) · Antonio Cittadini, MD (1) · Cecilia Lansang, MD (1) · Ference Peter, MD (1) · Guillem Cuatrecasas, MD (1) · Jungwon Woo (1) · Mihaly Juhasz, MD (1) · Peter J. Snyder, MD (1) · Steven K. Grinspoon, MD (1) · Torben Laursen, professor (1) · Xiaoping Luo, Doctor (1) · Xiaoping Luo, MD, Ph.D (1)
PMID 18053120, PMID 23015655, PMID 24178787, PMID 24291224, PMID 24423356, PMID 28566441, PMID 36034448
R01AR050618 (1), R01HL085268 (1)